Dinesh Patel, Protagonist CEO
April 25, 2022 04:25 PM EDT
R&D

Pro­tag­o­nist re­ports a PhII fail in ul­cer­a­tive col­i­tis, but ex­ecs are push­ing for­ward any­way

Max Gelman

Senior Editor

Pro­tag­o­nist Ther­a­peu­tics is hop­ing for a sec­ond chance in ul­cer­a­tive col­i­tis af­ter the biotech pulled the plug on its for­mer lead pro­gram four years ago …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times